Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Very low or no dividends
Very poor margins and returns
Weak growth
Risk / Profitability
Risk: High
Profitability: Average
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Significant default risk
Profitability factor
Very low or no dividends
Very poor margins and returns
Weak growth
$ 0.25
About
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process...
About
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune...
